Dr. Shen leads the business development team in finding, investing, and creating companies in the genetic disease space. She has created BridgeBio companies for several preclinical programs and been involved in acquiring clinical-stage programs. Dr. Shen’s academic training spans biochemistry (BS, National Taiwan University ’09) and systems neuroscience (Ph.D., Harvard University ’15). Her Ph.D. training was with Dr. Sharad Ramanathan; this work was published, see Kocabas, Shen et al., Nature, 2012.Kathleen Fleming, PhD
Dr. Fleming, a BD team member, champions programs internally for investment into start-ups, company creation, and sponsored research. She has created BridgeBio companies for preclinical programs. Dr. Fleming’s academic training spans Chemical-Engineering (SB, MIT ’11) and biochemistry (Ph.D., Harvard ’17). Her training was with Dr. Erin O’Shea, who is presently President of HHMI; this work was published, see Fleming and O’Shea, Cell Reports, 2018.